TIDMIXI

RNS Number : 7335X

IXICO plc

23 December 2019

23 December 2019

IXICO plc

("IXICO" or the "Company")

IXICO announces updates to client contracts

GBP2.4 million expansion of study programmes with two large pharma client contracts

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces:

-- cGBP1.8 million extension to a Phase III study in Huntington's Disease (HD), previously announced in September 2018; and

-- cGBP0.6 million extension to a study programme in Progressive Supranuclear Palsy (PSP), previously announced in October 2019.

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"HD and PSP are devastating neurological conditions, currently with no cure, and we are pleased to build momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease. Our services will enable them to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression.

"Following the recent announcement of our strong trading results for FY19, the expansion of these work programmes for two large pharma clients is further evidence of the value that we deliver through our proprietary AI data analytics and our ability to scale our operations to meet increasing size and complexity of clinical trials as they progress through clinical development."

For further information please contact:

 
 IXICO plc                                        +44 (0) 20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                +44 (0) 20 7397 8900 
 Giles Balleny / Max Gould (Corporate Finance) 
 Michael F Johnson / Russell Kerr (Sales) 
 
 Optimum Strategic Communications                  +44 (0) 203 950 9144 
 Mary Clark, Supriya Mathur, Manel Mateus 
 IXICO@optimumcomms.com 
 

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

CNTCKKDQOBDDABB

(END) Dow Jones Newswires

December 23, 2019 02:00 ET (07:00 GMT)

Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Ixico.
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Ixico.